Trials / Completed
CompletedNCT03155945
Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this randomized, open-label, parallel, phase 2a study is to determine the tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease experiencing abdominal pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olorinab | Olorinab active treatment for 8 weeks. |
Timeline
- Start date
- 2017-07-19
- Primary completion
- 2018-09-10
- Completion
- 2018-09-10
- First posted
- 2017-05-16
- Last updated
- 2021-11-02
- Results posted
- 2021-11-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03155945. Inclusion in this directory is not an endorsement.